L19-IL2 immunocytokine in combination with the anti-syndecan-1 46F2SIP antibody format: A new targeted treatment approach in an ovarian carcinoma model

Paola Orecchia, Enrica Balza, Gabriella Pietra, Romana Conte, Nicolò Bizzarri, Simone Ferrero, Maria Cristina Mingari, Barbara Carnemolla

Research output: Contribution to journalArticle

Abstract

Epithelial ovarian cancer (EOC) is the fifth most common cancer affecting the female population. At present, different targeted treatment approaches may improve currently employed therapies leading either to the delay of tumor recurrence or to disease stabilization. In this study we show that syndecan-1 (SDC1) and tumor angiogenic-associated B-fibronectin isoform (B-FN) are involved in EOC progression and we describe the prominent role of SDC1 in the vasculogenic mimicry (VM) process. We also investigate a possible employment of L19-IL2, an immunocytokine specific for B-FN, and anti-SDC1 46F2SIP (small immuno protein) antibody in combination therapy in a human ovarian carcinoma model. A tumor growth reduction of 78% was obtained in the 46F2SIP/L19-IL2-treated group compared to the control group. We observed that combined treatment was effective in modulation of epithelial-mesenchymal transition (EMT) markers, loss of stemness properties of tumor cells, and in alleviating hypoxia. These effects correlated with reduction of VM structures in tumors from treated mice. Interestingly, the improved pericyte coverage in vascular structures suggested that combined therapy could be efficacious in induction of vessel normalization. These data could pave the way for a possible use of L19-IL2 combined with 46F2SIP antibody as a novel therapeutic strategy in EOC.

Original languageEnglish
Article number1232
JournalCancers
Volume11
Issue number9
DOIs
Publication statusPublished - Sep 1 2019

Keywords

  • 46F2SIP anti-syndecan-1
  • Angiogenesis
  • L19-IL2 immunocytokine
  • Ovarian cancer
  • Syndecan-1 (SDC1)
  • Targeted therapy
  • Vascular mimicry
  • Vessels normalization

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'L19-IL2 immunocytokine in combination with the anti-syndecan-1 46F2SIP antibody format: A new targeted treatment approach in an ovarian carcinoma model'. Together they form a unique fingerprint.

  • Cite this